title: Structural and functional retinal changes in eyes with DUSN.
abstract: OBJECTIVE
  To report novel spectral domain optical coherence tomography and electrophysiologic findings in diffuse unilateral subacute neuroretinitis.
  
  
  METHODS
  Six patients with a diagnosis of diffuse unilateral subacute neuroretinitis were retrospectively ascertained. All patients had received oral treatment with albendazole; resolution of the inflammatory lesions without subsequent relapse was noted. Spectral domain optical coherence tomography was performed using a Spectralis HRA OCT (Heidelberg Engineering). The inner and outer retinal volumes were calculated for the macular area. The contralateral eyes acted as controls. All six patients underwent standardized full-field electroretinography and pattern electroretinography. Some had multifocal electroretinography.
  
  
  RESULTS
  Inner retinal volume significantly differed between affected and control eyes (P < 0.02), but there was no significant difference in outer retinal volume. Electroretinography data showed a mixed pattern of inner and outer retinal dysfunction, with inner retinal dysfunction being greater; reduction in b:a ratio of the scotopic bright flash electroretinography was a consistent observation in those patients (5/6) with generalized retinal dysfunction. Two patients showed definite photoreceptor involvement, with probable involvement in a third. Of the four patients in whom serial data are available, there was definite evidence of progressive inner and outer retinal dysfunction in one patient, with inner retinal dysfunction being greater, and probably in a second patient.
  
  
  CONCLUSIONS
  The data provide anatomical and functional evidence of both inner and outer retinal dysfunction in diffuse unilateral subacute neuroretinitis, even though the worm is usually assumed to be located in the subretinal space. The mechanism is unclear.
authors.affiliation: *Medical Retina Department, Uevitis Unit, Moorfields Eye Hospital, London, United Kingdom; and †Electrophysiology Department, Institute of Ophthalmology, University College London, London, United Kingdom.
authors.forename: Diego
authors.initials: D
authors.lastname: Vezzola
authors.forename: Nacima
authors.initials: N
authors.lastname: Kisma
authors.forename: Anthony G
authors.initials: AG
authors.lastname: Robson
authors.forename: Graham E
authors.initials: GE
authors.lastname: Holder
authors.forename: Carlos
authors.initials: C
authors.lastname: Pavesio
mesh_terms: D000284:Administration, Oral; D000328:Adult; D015766:Albendazole / Q000627:therapeutic use; D000981:Antiprotozoal Agents / Q000627:therapeutic use; D004596:Electroretinography; D015822:Eye Infections, Parasitic / Q000188:drug therapy / Q000469:parasitology / Q000503:physiopathology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012160:Retina / Q000187:drug effects / Q000503:physiopathology*; D012173:Retinitis / Q000188:drug therapy / Q000469:parasitology / Q000503:physiopathology*; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D014786:Vision Disorders / Q000503:physiopathology; D058609:Visual Field Tests; D014794:Visual Fields / Q000502:physiology; D055815:Young Adult
chemical_list: D000981:Antiprotozoal Agents; D015766:Albendazole